Sigilon Therapeutics has appointed Bioverativ chief global therapeutics operations officer , Rogerio Vivaldi , as CEO . Vivaldi takes the place of Paul Wotton, Ph.D., who plans to stay on at the Cambridge, Massachusetts-based company as an adviser while managing a family health issue, Sigilon said in a statement. It is poised to take its cell - based therapeutics implants to phase one trials , with a focus on cancer , haemophilia and lysosomal storage diseases . Meanwhile , Sigilon is developing a " living therapeutics " platform that delivers therapeutic proteins inside the body via genetically engineered cells , using polymer ##s to hide the proteins from the body 's immune system for at least a year .
Sigilon Therapeutics has appointed Bioverativ chief global therapeutics operations officer , Rogerio Vivaldi , as CEO . It is poised to take its cell - based therapeutics implants to phase one trials , with a focus on cancer , haemophilia and lysosomal storage diseases . Meanwhile , Sigilon is developing a " living therapeutics " platform that delivers therapeutic proteins inside the body via genetically engineered cells , using polymer ##s to hide the proteins from the body 's immune system for at least a year .